Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: An atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 303-308

  Douet Guilbert, Nathalie ^a,b,c   Basinko, Audrey ^a,b,c   Eveillard, Jean Richard ^b   Morel, Frédéric ^a,b,c   Le Bris, Marie Josée ^b   Guéganic, Nadia ^a   Bovo, Clément ^a   Herry, Angèle ^a   Berthou, Christian ^b   De Braekeleer, Marc ^a,b,c  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b CHU MORVAN   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; DEFERASIROX; ERYTHROPOIETIN; JANUS KINASE 2; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN;

5Q- SYNDROME; AGED; ANAMNESIS; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CELL LINEAGE; CHROMOSOME 5Q; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CYANOCOBALAMIN DEFICIENCY; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSERYTHROPOIESIS; DYSGRANULOPOIESIS; ERYTHROCYTE TRANSFUSION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GRANULOPOIESIS; HUMAN; IRON CHELATION; MACROCYTIC ANEMIA; MALE; MEGAKARYOCYTE; MULTIPLE CYCLE TREATMENT; PARACENTRIC CHROMOSOME INVERSION; PRIORITY JOURNAL; REFRACTORY ANEMIA;

EID: 78650025152     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.07.129     Document Type: Article

References (21)

1. Van den Berghe H., Vermaelen K., Mecucci C., Barbieri D., Tricot G. The 5q- anomaly. Cancer Genet Cytogenet 1985, 17:189-255.
2. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008, 87:515-526.
3. Giagounidis A.A., Germing U., Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006, 12:5-10.
4. Herry A., Douet-Guilbert N., Morel F., Le Bris M.J., Morice P., Abgrall J.F., et al. Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions. Cancer Genet Cytogenet 2007, 175:125-131.
5. Sole F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luno E., et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000, 108:346-356.
6. Hoffman M.W., Janney S., Batanian J.R. Cryptic deletion of EGR1 in association with a novel balanced t(5;22)(q31;q11.2) in a patient with myelodysplastic syndrome. Cancer Genet Cytogenet 2009, 191:106-108.
7. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009, 23:1252-1256.
8. Mohamedali A., Mufti G.J. Van-den Berghe's 5q- syndrome in 2008. Br J Haematol 2009, 144:157-168.
9. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
10. Eisenmann K.M., Dykema K.J., Matheson S.F., Kent N.F., Deward A.D., West R.A., et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene 2009, 28:3429-3441.
11. Mecucci C., Van den B.H., Michaux J.L., Bosly A., Doyen C. Paracentric inversions on the long arm of chromosome 5 in secondary myelodysplastic disorders. Cancer Genet Cytogenet 1987, 29:171-173.
12. Werner M., Maschek H., Kaloutsi V., Choritz H., Georgii A. Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance. Virchows Arch A Pathol Anat Histopathol 1992, 421:47-52.
13. Lu X., Lu D., Scully M., Kakkar V. The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem 2008, 2:57-73.
14. Kim M.M., Wiederschain D., Kennedy D., Hansen E., Yuan Z.M. Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP). Oncogene 2007, 26:4209-4215.
15. Boultwood J., Strickson A.J., Jabs E.W., Cheng J.F., Fidler C., Wainscoat J.S. Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q- syndrome within 5q32, and immediately adjacent to the SPARC gene. Hum Genet 2000, 106:127-129.
16. Tai I.T., Tang M.J. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 2008, 11:231-246.
17. Pellagatti A., Jadersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007, 104:11406-11411.
18. Kantarjian H., O'Brien S., Ravandi F., Borthakur G., Faderl S., Bueso-Ramos C., et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. Cancer 2009, 115:5202-5209.
19. Jadersten M., Saft L., Pellagatti A., Gohring G., Wainscoat J.S., Boultwood J., et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009, 94:1762-1766.
20. Eclache V., Da Rocha A., Le Roux G., Fenaux P. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q31 treated with lenalidomide. Haematologica 2008, 93:315-316.
21. Herry A., Douet-Guilbert N., Morel F., Le Bris M.J., De Braekeleer M. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol 2007, 78:457-467.